Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

[Complex karyotype is a marker of very poor prognosis in over 70-year-old patients with acute myeloid leukemia and extended types of myelodysplastic syndrome and high comorbidity index].

Tytuł :
[Complex karyotype is a marker of very poor prognosis in over 70-year-old patients with acute myeloid leukemia and extended types of myelodysplastic syndrome and high comorbidity index].
Autorzy :
Gritsaev SV
Martynkevich IS
Abdulkadyrov KM
Ivanova MP
Petrova EV
Zapreeva IM
Tiranova SA
Potikhonova NA
Pokaż więcej
Źródło :
Terapevticheskii arkhiv [Ter Arkh] 2012; Vol. 84 (7), pp. 16-21.
Typ publikacji :
English Abstract; Journal Article
Język :
Russian
Imprint Name(s) :
Publication: <2018- > : Moskva : ZAO 'Konsilium Medikum'
Original Publication: Moskva : Izdatelʹstvo Medit︠s︡ina
MeSH Terms :
Karyotype*
Antineoplastic Agents/*therapeutic use
Leukemia, Myeloid, Acute/*pathology
Myelodysplastic Syndromes/*pathology
Adolescent ; Adult ; Age Factors ; Aged ; Antineoplastic Agents/administration & dosage ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/physiopathology ; Comorbidity ; Female ; Follow-Up Studies ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Male ; Middle Aged ; Multivariate Analysis ; Myelodysplastic Syndromes/drug therapy ; Prognosis ; Retrospective Studies ; Survival Rate ; Treatment Outcome ; Young Adult
Substance Nomenclature :
0 (Antineoplastic Agents)
Entry Date(s) :
Date Created: 20121009 Date Completed: 20121023 Latest Revision: 20121212
Update Code :
20201020
PMID :
23038966
Czasopismo naukowe
Aim: To identify a category of persons with very low overall survival (OS) rates, whose intensive chemotherapy is unreasonable, amongst the patients with acute myeloid leukemia (AML) with extended forms of myelodysplastic syndrome (MDS) and complex karyotype.
Materials and Methods: OS rates were retrospectively analyzed in 41 patients with AML and 26 with MDS; their median age was 61 years (range 15 to 77 years). Thirty-four (50.7%) patients received standard induction courses; 19 (28.4%) patients had low-intensity therapy. Restraining therapy was used to treat 14 (20.9%) patients. The length of follow-up was 1.5 to 171 months.
Results: Irrespective of the type of disease, the median OS was 6 months. A difference in OS was found when the patients were divided into 4 age groups: those who were under 40 years of age (n = 11 ), 41-60 years (n = 21), 61-69 years (n = 21), and > or = 70 years (n = 14). With age, the median OS decreased from 9.5 to 4 months (p = 0.041). Multivariate analysis revealed that the intensity of induction courses was the cause that affected OS. High comorbidity index and, first of all, cardiovascular diseases were the main reason for discontinuing standard chemotherapy courses in patients aged 70 years or older.
Conclusion: Standard induction courses of cytostatic therapy are not indicated for patients aged > or = 70 years with AML and extended stages of MDS with complex karyotype and high comorbidity index.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies